Yujiro Nagata
Kitakyushu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
Journal: Cancer diagnosis & prognosis
Published: October 11, 2025
Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.
Journal: JMA journal
Published: September 22, 2025
Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.
Journal: Cureus
Published: August 11, 2025
Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.
Journal: Journal of kidney cancer and VHL
Published: June 25, 2025
Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent.
Journal: Cancer genomics & proteomics
Published: June 16, 2025
Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.
Journal: In vivo (Athens, Greece)
Published: March 19, 2025
Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: March 15, 2025
Sodium-Glucose Cotransporter 2 and Glucose Levels Affect Clear Cell Renal Cell Carcinoma Progression.
Journal: International journal of molecular sciences
Published: March 09, 2025
Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.
Journal: In vivo (Athens, Greece)
Published: February 15, 2025
Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Journal: Japanese journal of clinical oncology
Published: December 15, 2024
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Journal: International journal of molecular sciences
Published: August 28, 2024
Last Updated: 09/26/2026